Data / Form D filings / Typewriter Therapeutics, Inc.
Typewriter Therapeutics, Inc.: Form D filing
Typewriter Therapeutics, Inc., a biotechnology company in Cambridge, MA, filed a Form D with the SEC in 2026. The latest, on September 21, 2026, reports $56.3 million sold of a $56.3 million offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 238 MAIN STREET, OFFICE 2162, Cambridge, MA, 02142
- Phone
- (609) 923-9289
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2156390
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | New notice | $56,299,999 | $56,299,999 | 6 | Jan 8, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Matthew Stanton | Executive Officer, Director | |
| Kenneth Horne | Director | |
| Laura Tadvalkar | Director | |
| Mikael Dolston | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Sep 21, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Typewriter Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.